QBM 001

Drug Profile

QBM 001

Alternative Names: ASD-002-ASDERA/Q Biomed; ASD002; ASD02; Mefenamic acid prodrug - Q-Biomed; QBM-001

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ASDERA
  • Developer ASDERA; Q BioMed
  • Class Antimigraines; Antipyretics; Fenamates; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 19 Oct 2017 Q BioMed intends to complete preclinical studies in January 2018
  • 20 Sep 2017 Q Biomed plans a phase II/III trial for Migraines and Seizers in USA in 2018 (Q Biomed pipeline, September 2017)
  • 19 Sep 2017 Q BioMed and Sphaera enter into partnership for QBM 001 for paediatric autism spectrum disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top